ICHTHRALETTEN® 200 mg magensaftresistente Tabletten Wirkstoff: Natriumbituminosulfonat clinical trials

Phase 2, randomized, double-blind, placebo-controlled study of IC0624 as first-line therapy in patients with active mild to moderate Hidradenitis Suppurativa (HS)

This study is testing a new medication called IC0624 for people with a skin condition called Hidradenitis Suppurativa (HS). It's comparing the new medicine to a dummy pill to see if it helps reduce HS symptoms over six weeks.